Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
Who is this study for? Patients with suspected or confirmed pulmonary fibrosis
What treatments are being studied? 68Ga-FAPI+18F-FDG
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
68Ga-fibroblast activating protein inhibitors(FAPI) has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory bowel disease. And it might be more sensitive than FDG in detecting a certain type of inflammations according to our preliminary research. Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of Pulmonary fibrosis than 18F-FDG PET/CT.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• suspected or confirmed pulmonary fibrosis patients;
• signed written consent.
Locations
Other Locations
China
Peking Union Medical College Hospital
RECRUITING
Beijing
Contact Information
Primary
Zhaohui Zhu, MD
13611093752@163.com
86-13611093752
Backup
Jiarou Wang, MS
pumc_wangjiarou@student.pumc.edu.cn
86-13628477019
Time Frame
Start Date: 2021-11-18
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 80
Treatments
Experimental: 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT
All patients diagnosed with Lung fibrosis underwent 68Ga-FAPI PET/CT and 18F-FDG PET/CT.
Related Therapeutic Areas
Sponsors
Leads: Peking Union Medical College Hospital